ECSP066872A - Tabletas desintegrantes que comprenden licarbazepina - Google Patents

Tabletas desintegrantes que comprenden licarbazepina

Info

Publication number
ECSP066872A
ECSP066872A EC2006006872A ECSP066872A ECSP066872A EC SP066872 A ECSP066872 A EC SP066872A EC 2006006872 A EC2006006872 A EC 2006006872A EC SP066872 A ECSP066872 A EC SP066872A EC SP066872 A ECSP066872 A EC SP066872A
Authority
EC
Ecuador
Prior art keywords
licarbazepina
understanding
disintegrant
tablets
disintegrant tablets
Prior art date
Application number
EC2006006872A
Other languages
English (en)
Inventor
Oskar Kalb
Marie-Christine Wolf
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0406381A external-priority patent/GB0406381D0/en
Priority claimed from GB0406737A external-priority patent/GB0406737D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP066872A publication Critical patent/ECSP066872A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

Abstract

La invención se refiere a composiciones farmacéuticas que comprenden 10,11-dihidro-10-hidroxi-5H-dibenz[b,f]azepina-5-carboxamida (también referida como "licarbazepina") como sustancia de fármaco.
EC2006006872A 2004-03-22 2006-09-21 Tabletas desintegrantes que comprenden licarbazepina ECSP066872A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0406381A GB0406381D0 (en) 2004-03-22 2004-03-22 Organic compounds
GB0406737A GB0406737D0 (en) 2004-03-25 2004-03-25 Organic compounds

Publications (1)

Publication Number Publication Date
ECSP066872A true ECSP066872A (es) 2006-11-24

Family

ID=34962439

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006872A ECSP066872A (es) 2004-03-22 2006-09-21 Tabletas desintegrantes que comprenden licarbazepina

Country Status (16)

Country Link
US (1) US20070190143A1 (es)
EP (1) EP1729737A1 (es)
JP (1) JP2007529563A (es)
AR (1) AR048672A1 (es)
AU (1) AU2005226909B2 (es)
BR (1) BRPI0509014A (es)
CA (1) CA2558307A1 (es)
EC (1) ECSP066872A (es)
IL (1) IL177830A0 (es)
MA (1) MA28526B1 (es)
MX (1) MXPA06010809A (es)
NO (1) NO20064783L (es)
PE (1) PE20060124A1 (es)
RU (1) RU2006137329A (es)
TW (1) TW200534859A (es)
WO (1) WO2005092290A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0221956D0 (en) * 2002-09-20 2002-10-30 Novartis Ag Organic compounds
AR048318A1 (es) * 2004-03-22 2006-04-19 Novartis Ag Formulaciones de matriz orales que comprenden licarbazepina
PT2380575E (pt) * 2005-05-06 2015-06-17 Bial Portela & Ca Sa Acetato de eslicarbazepina e utilização
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
US8372431B2 (en) * 2007-10-26 2013-02-12 Bial-Portela & C.A., S.A. Pharmaceutical composition comprising licarbazepine acetate
RU2625747C2 (ru) * 2010-12-31 2017-07-18 БИАЛ-ПОРТЕЛА энд КА., С.А. Грануляты, содержащие эсликарбазепина ацетат
JP2013237676A (ja) * 2013-06-26 2013-11-28 Bial-Portela & Ca Sa 酢酸エスリカルバゼピン及び使用方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH649080A5 (de) * 1981-04-16 1985-04-30 Ciba Geigy Ag 5h-dibenz(b,f)azepin-5-carboxamide als mittel zur prophylaxe und behandlung von zerebraler leistungsinsuffizienz.
US6296873B1 (en) * 1997-01-23 2001-10-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Zero-order sustained release delivery system for carbamazephine derivatives
CO4920215A1 (es) * 1997-02-14 2000-05-29 Novartis Ag Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones
IL125244A (en) * 1998-07-07 2002-12-01 Yissum Res Dev Co Pharmaceutical compositions containing low-melting waxes
GB9925962D0 (en) * 1999-11-02 1999-12-29 Novartis Ag Organic compounds
US20030190343A1 (en) * 2002-03-05 2003-10-09 Pfizer Inc. Palatable pharmaceutical compositions for companion animals
BR0311327A (pt) * 2002-05-31 2005-02-22 Desitin Arzneimittel Gmbh Composição farmacêutica contendo oxcarbazepina com liberação sustentada de um ingrediente ativo
GB0221956D0 (en) * 2002-09-20 2002-10-30 Novartis Ag Organic compounds
US20050214388A1 (en) * 2004-02-18 2005-09-29 Gorham Thomas R Multivitamin formulations containing controlled-release magnesium
AR048318A1 (es) * 2004-03-22 2006-04-19 Novartis Ag Formulaciones de matriz orales que comprenden licarbazepina

Also Published As

Publication number Publication date
IL177830A0 (en) 2006-12-31
PE20060124A1 (es) 2006-03-07
AU2005226909A1 (en) 2005-10-06
AU2005226909B2 (en) 2009-05-14
CA2558307A1 (en) 2005-10-06
MA28526B1 (fr) 2007-04-03
AR048672A1 (es) 2006-05-17
NO20064783L (no) 2006-12-15
BRPI0509014A (pt) 2007-08-07
EP1729737A1 (en) 2006-12-13
JP2007529563A (ja) 2007-10-25
RU2006137329A (ru) 2008-06-20
MXPA06010809A (es) 2006-12-15
US20070190143A1 (en) 2007-08-16
WO2005092290A1 (en) 2005-10-06
TW200534859A (en) 2005-11-01

Similar Documents

Publication Publication Date Title
AP2405A (en) Cannabinoid active pharmaceutical ingredient for improved dosage forms.
BR0015188A (pt) Composições farmacêuticas
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
EP1477403A4 (en) MEDICINES SUPPLY
DK1521573T3 (da) Ikke-polymere, lipofile, farmaceutiske implantatsammensætninger til intrakulær anvendelse
DE60205870D1 (de) Orale pharmazeutische zusammensetzung aus cefpodoxim-proxetil
PT1500654E (pt) Derivados de benzoxazinona, sua preparacao e utilizacao como medicamentos
DE502007005902D1 (de) -methyl-19-nor-20- spirox-4-en-3-one), sowie diese enthaltende pharmazeutische präparate
WO2006138735A3 (en) Gel compositions for topical administration
ATE252377T1 (de) Kontrolliert freisetzende pharmazeutische zusammensetzung mit tilidinmesylat als wirkstoff
BRPI0620229A8 (pt) formulação
ECSP066860A (es) Formulaciones de matriz oral que comprenden licarbazepina
ECSP066872A (es) Tabletas desintegrantes que comprenden licarbazepina
CR8371A (es) Formulaciones de medicamento que contienen saborizantes con mejores propiedades farmaceuticas
TW200503783A (en) Oral pharmaceutical preparation for proton pump antagonists
EA200100802A1 (ru) Применение тианептина при приготовлении лекарственных средств, предназначенных для лечения нейродегенеративных патологий
UY30023A1 (es) Nueva asociacion de un inhibidor de la corriente sinusal i, y de un inhibidor calcico y las composiciones farmaceuticas que la contienen
WO2007007182A3 (en) Solid and liquid dosage forms of an antiepileptic agent
UA87152C2 (ru) Твердая фармацевтическая композиция, содержащая миртазапин, и способ ее получения
TNSN06298A1 (en) Disintegrating tablets comprising licarbazepine
ATE357220T1 (de) Pharmazeutische zusammensetzung mit modifizierter freisetzung
ATE489943T1 (de) Pharmazeutische zusammensetzung mit 2,3-dihydro-6-nitroimidazoä2,1-büoxazolderivate
TNSN06299A1 (en) Oral matrix formulations comprising licarbazepine
WO2007093168A3 (de) Schnell freisetzende irbesartan-haltige pharmazeutische zusammensetzung
CL2003002295A1 (es) Derivados de bencenosulfonil-carbamoil-gamma-aminopropil sustituidos de 9-deoxo-9-dihidro-9a-aza-9a-homoeritromicina a y 5-o-desosaminil-9-deoxo-9-dihidro-9a-aza-9a-homoeritronolida a, composicion farmaceutica, procedimiento de preparacion, utiles pa